Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

Pralsetinib

SKU: orb1296082

Description

Pralsetinib (BLU-667) is a potent and selective RET kinase inhibitor effective against wild-type RET, multiple mutants (V804L, V804M, M918T), and the CCDC6-RET fusion. It is a valuable research tool for investigating RET-driven pathologies, with demonstrated activity in both cellular assays and in vivo models of RET-altered cancers.

Research Area

Cell Biology, Pharmacology & Drug Discovery, Signal Transduction

Images & Validation

Key Properties

CAS Number2097132-94-8
MW533.6
Purity99.89% (May vary between batches)
FormulaC27H32FN9O2
SMILESCO[C@]1(CC[C@@H](CC1)c1nc(C)cc(Nc2cc(C)[nH]n2)n1)C(=O)N[C@@H](C)c1ccc(nc1)-n1cc(F)cn1
Targetc-RET
Solubility10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (6.18 mM);DMSO:126.25 mg/mL (236.6 mM)

Bioactivity

Target IC50
CCDC6-RET:0.4 nM|RET (M918T):0.4 nM|RET (WT):0.4 nM|RET (V804M):0.4 nM|RET (V804L):0.3 nM
In Vivo
Pralsetinib potently inhibits the growth of NSCLC and thyroid cancer xenografts driven by various RET mutations and fusions without inhibiting VEGFR-2. Pralsetinib shows dose-dependent activity against both KIF5B-RET Ba/F3 and KIF5B-RET V804L Ba/F3 allograft tumors with doses as low as 10 mg/kg twice daily.
In Vitro
Pralsetinib demonstrates more than 10-fold increased potency over approved MKIs against oncogenic RET variants and resistance mutants. Pralsetinib demonstrates potent activity (IC50: 0.4 nM) against common oncogenic RET alterations, including RET M918T, an activating mutation found in MTC, as well as the CCDC6-RET fusion observed in PTC and NSCLC. Pralsetinib suppresses RET pathway signaling in a panel of RET-driven cell lines: LC2/ad (CCDC6-RET, NSCLC), MZ-CRC-1 (RET M918T, MTC), and TT (RET C634W, MTC).

Storage & Handling

Storage-20°C
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

Inhibitor, inhibit, cRET, Blu667, BLU-667, BLU 667, Pralsetinib, RET

Similar Products

  • TPX-0046 (enantiomer) [orb1304091]

    99.95% (May vary between batches)

    2359650-19-2

    424.43

    C21H21FN6O3

    1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 2 mg
  • trans-Pralsetinib [orb1710042]

    98.06% (May vary between batches)

    2097132-93-7

    533.6

    C27H32FN9O2

    2 mg, 1 ml x 10 mM (in DMSO)
  • Pralsetinib HCl (2097132-94-8 free base) [orb1983618]

    570.07

    C27H33ClFN9O2

    100 mg, 500 mg
  • Pralsetinib [orb1220057]

    >98% (HPLC)

    2097132-94-8

    533.6

    C27H30FN9O2

    10 mg, 25 mg, 50 mg, 100 mg, 2 mg, 5 mg, 200 mg, 500 mg, 1 g
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Key Properties

No computed properties available.

Protocol Information

Available Sizes

Select a size below

1 mg
$ 80.00
5 mg
$ 150.00
1 ml x 10 mM (in DMSO)
$ 170.00
10 mg
$ 190.00
25 mg
$ 340.00
50 mg
$ 510.00
100 mg
$ 740.00
DispatchUsually dispatched within 5-10 working days
Bulk Enquiry